Breakthrough research could make any IV drug able to be taken orally for a range of hard-to-treat cancers and other diseases, and redefine how medicines are designed, evaluated and delivered.

Gain expert insights in this interview on achieving transfection success. Explore proven strategies to optimize your approach ...

Private equity firm KKR has offered to buy all shares in Swedish life sciences company Biotage for Skr11.6bn ($1.2bn).

A research team led by scientists at The University of Texas Health Science Center at San Antonio (UT Health San ...

A research team led by scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) made a major breakthrough with the potential to turn IV drugs into oral ...

First Quarter 2025 Results Key Financial Results Revenue: US$24.0m (up 12% from ...

The researchers identified the structure of this machine, the mitochondrial pyruvate carrier (MPC), and 50 years since its discovery, have shown how it operates like the lock on a canal to transport ...

Demis Hassabis said that AI could lead to ‘radical abundance,’ while also posing various risks in the medical sector.

Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeuticsFocus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential ...

Demis Hassabis, the co-founder and CEO of Google DeepMind, has made an audacious claim that artificial intelligence could ...

Headquartered in Sweden, Biotage is listed on NASDAQ Stockholm. KKR has made a $1.2 billion offer for Biotage.

Lin said that it costs about $2 billion to develop a drug in the private sector, while NIH-funded research produces a drug at ...